Articles On Monash IVF Group (ASX:MVF)

This seems like an excellent time to pick up discounted ASX dividend shares while high interest rates have pushed down on the valuations of certain sectors. I'm going to talk about two stocks with share prices under $2. While the share p...

The S&P/ASX 200 Health Care Index rose 2.89% in November as momentum returned to the sector Health cryogenic services company Vitrafy and nerve-repair biotech Renerve debuted on the ASX  Paradigm Biopharmaceuticals rose 151% in Novembe...

Are you on the lookout for some new additions to your portfolio in December? If you are, it could pay to look at the two ASX 300 shares that brokers have just put buy ratings on. Here's what they are saying about them: Monash IVF Group Ltd...

The ASX healthcare share Monash IVF Group Ltd (ASX: MVF) could be an underrated ASX dividend share, in my eyes. If we look at the chart below, we can see that Monash IVF briefly touched a 52-week low of $1.11 yesterday. In the last...

ASX healthcare stocks underperform but optimism grows Uscom, Respiri and Hitiq report mixed results Artrya and Nyrada make key clinical advances   The S&P/ASX 200 Health Care [XHJ] index was down 0.9% gain in October. For the year, th...

Control Bionics says it has overcome the “challenges” of the 2023-24 year Ord Minnett identifies the health sector stunners Noxopharm finds a drug manufacturer to kick-start its lupus trial   Health Check is renowned biotech journo Tim Bo...

Greenbox Architecture, a full-service firm that has worked on the likes of Monash IVF's (ASX: MVF) flagship facility and NEXTDC's (ASX: NXT) most recently built Sydney data centre, has been acquired by US-headquartered Woolpert for an undis...

ResMed unveils its 2030 strategy with revenue expected to grow in high single digits for the next five years With a weaker share price Power said Monash IVF could provide a buying opportunity ahead of its AGM in November  ASX health stocks...

Healthcare stocks are doing relatively well globally in 2024
 The sector could see more recovery as Fed cuts rates
 How ASX biotechs performed in the month of September   The S&P 500 Health Care Index, a key world benchmark for health...

The S&P/ASX 200 Index (ASX: XJO) is having a better day on Thursday. In afternoon trade, the benchmark index is up 0.2% to 7,965.5 points. Four ASX shares that have failed to follow the market higher today are listed below. Here's why...

ASX health stocks rise at time of publishing, in line with broader markets amid mixed reporting season EBOS FY24 result in line with consensus as it looks to fill hole by loss of Chemist Warehouse contract Healius says pathology needs more...

The ASX200 has once again closed higher, up 0.21% at 8,027 points. The IT sector was the strongest performer up 1.9%, followed by Industrials 1.3% and Real Estate 0.8%. Utilities was the poorest performer and finished the day around a...

The All Ordinaries Index (ASX: XAO) is up 0.4% in early afternoon trade, but it's not getting any help from this crashing ASX All Ords stock. The company in question is Monash IVF Group Ltd (ASX: MVF). Before market open this mornin...

Australian shares are set to rise as US stocks gained in afternoon trade, buoyed by revisions to jobs data that largely met expectations. This development reinforces the view that the US labor market is cooling, increasing the likelihood th...

S&P/ASX 200 Health Care index up 5pc in July, 9.5pc YTD Health sector gains momentum with expected Fed rate cuts; ResMed seen as a strong buy And ASX healthcare winners and losers in July   The S&P/ASX 200 Health Care index [XHJ]...

The EMA has rejected the Alzheimer’s drug Leqembi, developed by Eisai and Biogen There is one ASX-listed company that collaborates with Eisai We take a look at the best performing ASX health stocks in the past month   In a major blow for...

The ASX Health Care index saw a 4% increase in June Growth was driven by CSL and Cochlear Best biotechs in June were Actinogen, Optiscan and EZZ Life Science, amongst others    The S&P/ASX 200 Health Care index [XHJ] saw a 4% increase...

ASX Health sector was in correction territory in April Why is the health sector different from other sectors? We look at the best performing ASX health stocks for the month   The S&P/ASX 200 Health Care [XHJ] had a soft month in April...

There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to control sebum production We look at the best and worst performing ASX health stocks in the past month   Scientists have made a significant b...

It's looking like this Tuesday will be another positive day for the Australian share market and most ASX All Ords shares. At the time of writing, the All Ordinaries Index (ASX: XAO) has risen by a healthy 0.4%, leaving the index at just ove...

  US markets opened in positive territory before Fed rates commentary and a pop in oil prices spooked traders and triggered an afternoon sell off. The Dow Jones finished the day down 1.4 per cent, the S&P500 closed down 1.2 per cent aft...

The ASX 200 lifted modestly by +0.2% on Thursday as gains in Tech and Industrial stocks were offset by losses in Energy.  Local traders brushed out dovish comments from Fed Chair Jerome Powell last night. Appearing before Congress, Powell r...

  The S&P 500 rose Wednesday as investors attempted to turn a corner following back-to-back losing sessions on Wall Street. The S&P 500 added 0.51 per cent to 5,104.76, while the Nasdaq Composite gained 0.58 per cent to 16,031.54. T...

Note: Figures recorded at 7:40am AEDT. Updated figures and a video recording will be available at 9am AEDT. The S&P 500 rose Wednesday as investors attempted to turn a corner following back-to-back losing sessions on Wall Street. The br...

ASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essentially, biotech is a long term game for investors   The S&P/ASX 200 Health Care [XHJ] struggled in February, finishing -1.5% lower and tr...

QBE Insurance elevated to S&P/ASX 20 as gold miner Newmont removed Flight Centre and Pro Medicus both make the S&P/ASX 100 in March rebalance Several tech companies make benchmark S&P/ASX 200 but not so good for resources  Mar...

Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks   There were a couple of big news from the world of biotec...

Today, Monday the 26th of February 2024, we are happy to buy Wagners (ASX:WGN), Bapcor Limited (ASX:BAP), Super Retail Group (ASX:SUL), Cedar Woods Properties (ASX:CWP), Accent Group (ASX:AX1), Avita Medical (ASX:AVH), Jumbo Interactive (AS...

ASX gains on Nvidia-fuelled rally AI adjacent stocks, such as data centre companies, also surge Afterpay parent Block Inc surges 17pc, Newmont crashes 7pc   The ASX 200 gained around 0.4% as the AI craze swept through global stock markets...

ASX health sector flat for week as broader market falls during volatile reporting season Avita Medical reports strong full year FY23 results, forecast to reach cashflow breakeven in FY25 Clinuvel Pharmaceutical H1 FY24 results below consen...

ASX health sector falls broader market with some key names ailing in reporting season CSL Phase III trial fails to meet primary efficacy endpoint but delivers solid H1 FY24 results Neuren Pharmaceuticals falls 13% on Friday after short sel...

Xi and Biden set to agree on restricting fentanyl  Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks   China’s President Xi is expected...

ASX small-cap shares can be a great area of the share market to find little-known opportunities that could deliver strong long-term returns in the form of both dividends and capital growth. Big businesses like Commonwealth Bank of Australi...

  US stocks rose Tuesday, boosted by declines in Treasury yields as Wall Street assessed the geopolitical risks from the Israel-Hamas war. The benchmark 10-year Treasury yield fell nearly 13 basis points to about 4.65 per cent, as investors...

Voltaic Strategic Resources to release more than 31 million fully paid ordinary shares Besra Gold to release more than 51 million CDIs in escrow since the company listed Fertility company Monash IVF to release around 500,000 fully paid ord...

L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks   Be...

This Tuesday's trading session has been a pretty depressing one for the All Ordinaries Index (ASX: XAO) and most ASX All Ords shares. At present, the All Ords has lost a notable 0.42% and is back under 7,400 points. But there are a few ASX...

The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks   On...

The ASX is set to open higher on Tuesday It was all about Tesla on Wall Street overnight, as the stock jumps 10pc Morgan Stanley says healthcare stocks are undervalued   Australian shares are set to open higher on Tuesday after a rally on...

  Stocks sold off Wednesday, continuing the sluggish start to September, as concerns mounted that the Federal Reserve may not be done hiking interest rates. The Dow Jones Industrial Average sank 198.78 points, or 0.57 per cent, to end at 34...

Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August   August was all about earnings, and des...

Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the  best and worst performing ASX biotechs over the past month   The Australian biotech sector co...

ASX health sector falls in mixed week of FY23 results as reporting season continues Monash IVF reports solid FY23 result and forecasts higher IVF cycles going forward Ramsay healthcare plunges on disappointing FY23 result and cut in final...

Monash IVF's (ASX:MVF) FY23 was in line with guidance of underlying NPAT of $25.5m (up 14.%).

Today, Wednesday the 23rd of August, we are happy to buy BHP Group (ASX:BHP), Data#3 Limited (ASX:DTL), Objective Corporation (ASX:OCL), and Monash IVF (ASX:MVF).

ASX health sector outperforming the broader market but remain flattish for week CSL reports solid FY23 results after record plasma collections and lift in sales  Cochlear FY23 sales revenue increases 19% on pcp to a record $1.956 billion...

Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month   Steve Jobs used to say that the most...

The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July   The Covid-19 pandemic had produced windfalls for and attracted fa...

Brisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “game changer” We look at the best and worst performing ASX biotechs over the past month   The world is anticipating a “game changer” as Brisba...

Small cap health stocks are not known to pay dividends But there’s a handful of such stocks on the ASX that do pay dividends We look at the best and worst performing ASX biotechs over the past week   When we talk about dividend-paying hea...